<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896660</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00018757</org_study_id>
    <nct_id>NCT02896660</nct_id>
  </id_info>
  <brief_title>Probuphine Innovations for Clinical Effectiveness (PRINCE)</brief_title>
  <acronym>PRINCE</acronym>
  <official_title>Activity Monitors for Opioid Dependence Treated With Probuphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthcare Innovation Technology Lab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Braeburn Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Healthcare Innovation Technology Lab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HITLAB will conduct a crossover study wherein participants will be asked to wear an&#xD;
      actigraphy device continuously for 12 weeks. The first four weeks of the study participants&#xD;
      will continue their previously scheduled treatment regimen, prior to receiving the Probuphine&#xD;
      implant. Following four weeks of activity and sleep baseline monitoring using the actigraphy&#xD;
      device, the participant will receive the Probuphine implant as part of their regularly&#xD;
      scheduled treatment plan. Observation of the participant's activity levels will continue for&#xD;
      eight weeks following implantation of Probuphine. Actigraphy measurements will include total&#xD;
      time asleep, total time awake, sleep efficiency, and time mobile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HITLAB will conduct a crossover study that measures the activity levels and sleep quality of&#xD;
      patients both before and during treatment with Probuphine in order to determine whether&#xD;
      Probuphine offers the additional benefit of improved energy levels during treatment, further&#xD;
      distinguishing it from other opioid dependency treatments.&#xD;
&#xD;
      HITLAB researchers will meet with participating site physicians prior to study recruitment in&#xD;
      order to administer the &quot;Physician Baseline Questionnaire,&quot; a brief semi-structured baseline&#xD;
      questionnaire to assess initial physician expectations for the actigraphy device.&#xD;
&#xD;
      Per physician guidelines, patients must be in stable treatment for at least 1 month prior to&#xD;
      study enrollment. If the physician determines Probuphine to be an appropriate treatment&#xD;
      method for the study subject, the physician will meet with the subject and explain the&#xD;
      purpose of the actigraphy.&#xD;
&#xD;
      Upon enrollment, the physician will administer the &quot;Participant Baseline Questionnaire,&quot;&#xD;
      assessing general well-being, physical activity level, sleep patterns, and technology usage.&#xD;
      At this time, the participant will be asked to begin wearing the Actigraph continuously for&#xD;
      12 weeks. The first four weeks of the study patients will continue their previously scheduled&#xD;
      treatment regimen, prior to receiving the Probuphine implant.&#xD;
&#xD;
      Following four weeks of activity and sleep baseline monitoring using the actigraph device,&#xD;
      the participant will receive the Probuphine implant [day 30]. At this visit, the clinician&#xD;
      will administer four clinical assessments: Assessment of Withdrawal from Opioids Scale&#xD;
      (SOWS), Clinical Opiate Withdraw Scale (COWS), Visual Analog Scales (VAS), and Measures of&#xD;
      Morning Desire to use/need to use tool from Braeburn Pharmaceuticals (HS-11-421), as well as&#xD;
      a baseline quality of life assessment (WHOQOL-BREF).&#xD;
&#xD;
      Observation of the participant's activity levels will continue for a total of eight weeks&#xD;
      following implantation of Probuphine. Actigraphy measurements will include total time asleep,&#xD;
      total time awake, sleep efficiency, and time mobile.&#xD;
&#xD;
      At the midline 60-day visit with each participant, as part of their regular monthly treatment&#xD;
      appointment, the physician will repeat administration of the four clinical assessments (The&#xD;
      Assessment of Withdrawal from Opioids Scale (SOWS), Clinical Opiate Withdraw Scale (COWS),&#xD;
      Visual Analog Scales (VAS), and Measures of Morning Desire to use/Need to use tool from&#xD;
      Braeburn Pharmaceuticals (HS-11-421)), as well as the quality of life assessment&#xD;
      (WHOQOL-BREF).&#xD;
&#xD;
      At the participant endline visit [90 days], a physician will administer a repeat quality of&#xD;
      life questionnaire (WHOQOL-BREF), and the four clinical assessments: Assessment of Withdrawal&#xD;
      from Opioids Scale (SOWS), Clinical Opiate Withdraw Scale (COWS), Visual Analog Scales (VAS),&#xD;
      and Measures of Morning Desire to use/need to use tool from Braeburn Pharmaceuticals&#xD;
      (HS-11-421).&#xD;
&#xD;
      In addition, five participants will be randomly selected to participate in a short&#xD;
      qualitative interview at the time of the site endline visit. Participant interviews, in&#xD;
      person or via telephone, will assess their experience using the actigraph device during&#xD;
      treatment, and their perspectives on activity changes and sleep quality. Patient perspectives&#xD;
      on activity changes and sleep quality will serve as a point of triangulation for the&#xD;
      actigraphy data.&#xD;
&#xD;
      HITLAB will conduct a baseline site visit, a site visit after 30 days, after 60 days, and&#xD;
      after 90 days (the endline visit) of the study period to collect questionnaire and assessment&#xD;
      data for analysis. Actigraphy data will be uploaded at days 30, 60 and 90. At the endline&#xD;
      site visit, participating physicians will be asked to complete a brief, semi-structured&#xD;
      &quot;Physician Endline Questionnaire&quot; to assess satisfaction with the actigraphy device in&#xD;
      helping them improve outcomes and quality of life for patients in Probuphine treatment. A&#xD;
      HITLAB researcher will also conduct a brief qualitative interview with the physicians at the&#xD;
      endline site visit. The in-person physician interviews will assess whether the actigraphy&#xD;
      data informed patient experience in such a way that it improves the efficacy of Probuphine&#xD;
      administration and treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with changes in energy levels, as assessed by ActiGraph Link GT9X-BT</measure>
    <time_frame>90 days</time_frame>
    <description>Patients will wear an actigraphy device to assess changes in activity over a 90-day period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in sleep quality, as assessed by ActiGraph Link GT9X-BT</measure>
    <time_frame>90 days</time_frame>
    <description>Patients will wear an actigraphy device to assess changes in sleep quality over a 90-day period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in quality of life, as assessed by WHOQOL-BREF</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with changes in self-reported desire/need to use symptoms, as assessed by Assessment of Withdrawal from Opioids Scale (SOWS)</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with changes in clinician-reported desire/need to use symptoms, as assessed by Clinical Opiate Withdrawal Scale (COWS)</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>ActiGraph Link</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiGraph Link</intervention_name>
    <description>Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.</description>
    <arm_group_label>ActiGraph Link</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible subjects must:&#xD;
&#xD;
          1. Be Adults over the age of 18&#xD;
&#xD;
          2. Speak English&#xD;
&#xD;
          3. In treatment for opioid addiction/dependence&#xD;
&#xD;
          4. Meet the criteria for treatment with Probuphine (on 8mg or less Subutex or Suboxone&#xD;
             sublingual tablet or generic equivalent not requiring dose adjustment x 1 month)&#xD;
&#xD;
          5. Be clinically stable&#xD;
&#xD;
          6. Be willing to follow study procedures-including wearing a wearable actigraphy&#xD;
             device-for 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Potential subjects must not:&#xD;
&#xD;
          1. Be less than 18 years of age&#xD;
&#xD;
          2. Do not meet the criteria for opioid dependence based on APA guidelines&#xD;
&#xD;
          3. Do not meet the criteria for treatment with Probuphine&#xD;
&#xD;
          4. Are not clinically stable or suffer from other mitigating issues surrounding addiction&#xD;
             or psychological state.&#xD;
&#xD;
          5. Are not willing to follow study procedures-including wearing a wearable actigraphy&#xD;
             device-for 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stan Kachnowski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Healthcare Innovation Technology Lab</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Chokshi, PhD</last_name>
    <phone>212-543-0100</phone>
    <phone_ext>30</phone_ext>
    <email>schokshi@hitlab.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen A Lynch, MS</last_name>
    <phone>212-543-0100</phone>
    <phone_ext>16</phone_ext>
    <email>klynch@hitlab.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Hartwell EE, Pfeifer JG, McCauley JL, Moran-Santa Maria M, Back SE. Sleep disturbances and pain among individuals with prescription opioid dependence. Addict Behav. 2014 Oct;39(10):1537-42. doi: 10.1016/j.addbeh.2014.05.025. Epub 2014 Jun 2.</citation>
    <PMID>24999989</PMID>
  </reference>
  <reference>
    <citation>Wilson KG, Watson ST, Currie SR. Daily diary and ambulatory activity monitoring of sleep in patients with insomnia associated with chronic musculoskeletal pain. Pain. 1998 Mar;75(1):75-84. doi: 10.1016/S0304-3959(97)00207-8.</citation>
    <PMID>9539676</PMID>
  </reference>
  <reference>
    <citation>Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003 May 1;26(3):342-92. Review.</citation>
    <PMID>12749557</PMID>
  </reference>
  <reference>
    <citation>Valli√®res A, Morin CM. Actigraphy in the assessment of insomnia. Sleep. 2003 Nov 1;26(7):902-6.</citation>
    <PMID>14655927</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All participant data will be anonymous and reported in aggregate.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

